search
Back to results

Intelligent Spine Interface (ISI)

Primary Purpose

Spinal Cord Injury

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Intelligent Spine Interface
Sponsored by
Rhode Island Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Spinal Cord Injury

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • • Adults (men or women) between the ages of 18 and 65 years old

    • Complete or Incomplete SCI with AIS grade of A or B between the levels of C7/T1 and T10 (level and degree of injury based on the international standards for neurological classification of SCI (ISNCSCI))
    • Focal area of SCI due to trauma
    • SCI date of injury > 1 year prior to enrollment
    • Completed prior SCI rehabilitation program
    • Ability to use both upper extremities to ambulate with a wheelchair or crutches
    • Distance between the conus medullaris and site of injury must be > 4 cm
    • The ability to participate in intensive physical therapy and research > 4 hours per day for 2 weeks
    • Must provide informed consent prior to study participation

Exclusion Criteria:

  • • Presence of co-existing lower extremity neuropathy or disorders of the cauda equina

    • Presence of non-traumatic spinal cord pathology
    • Significant cognitive impairment or decreased level of consciousness
    • Presence of an intrathecal baclofen or morphine pump
    • Presence of a cardiac defibrillator or pacemaker
    • Presence of a deep brain stimulator device
    • Patient who has any contraindication to having a MRI performed
    • Severe or disabling joint contractures in the lower extremities
    • Presence of hematologic disorder or medication related coagulopathy that would preclude surgery
    • Lower extremity congenital or acquired deformities
    • Women who are pregnant or who are unwilling to use contraception during the study period
    • Body mass index > 30
    • Cardiopulmonary comorbidities that preclude participation in intensive physical therapy
    • Known or suspected patient non-compliance during the study period and at follow up
    • Patient life expectancy < 12 months
    • Presence of patient comorbidities or spinal anatomy that would preclude participation in the study per investigators' recommendation

Sites / Locations

  • Rhode Island HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

SCI Patient

Arm Description

Complete or Incomplete Spinal Cord Injury (SCI) patients with Asia Impairment Score (AIS) of A or B between the levels of C7/T1 and T10

Outcomes

Primary Outcome Measures

Evaluate safety issues
Evaluate safety issues associated with the implantation and use of ISI technology i.e. frequency of device related adverse events

Secondary Outcome Measures

Neurological Outcome Measures
Assess neurological outcomes before, during, and after ISI implantation in SCI patients via ISNCSCI evaluation
Functional Outcome Measures
Assess functional outcomes before, during, and after ISI implantation in SCI patients via 6 Minute Walk Test
Functional Outcome Measures
Assess functional outcomes before, during, and after ISI implantation in SCI patients via 10 minute timed walk test
Functional Outcome Measures
Assess functional outcomes before, during, and after ISI implantation in SCI patients via Time Up and Go test
Functional Outcome Measures
Assess functional outcomes before, during, and after ISI implantation in SCI patients via Spinal cord Injury Functional Ambulation Inventory
Functional Outcome Measures
Assess functional outcomes before, during, and after ISI implantation in SCI patients via Spinal Cord Injury Quality of Life (SCI-QOL): Ambulation Short Form
Functional Outcome Measures
Assess functional outcomes before, during, and after ISI implantation in SCI patients via SCI Functional Ambulatory Inventory (FAI)
Functional Outcome Measures
Assess functional outcomes before, during, and after ISI implantation in SCI patients via Berg Balance Scale
Functional Outcome Measures
Assess functional outcomes before, during, and after ISI implantation in SCI patients via Mini-Best test

Full Information

First Posted
February 19, 2020
Last Updated
October 23, 2022
Sponsor
Rhode Island Hospital
Collaborators
US Department of Veterans Affairs, Brown University, Intel Corporation, Nuvectra, Boston Scientific Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT04302259
Brief Title
Intelligent Spine Interface
Acronym
ISI
Official Title
An Early Feasibility Study to Evaluate ISI-C in SCI Patients
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2021 (Actual)
Primary Completion Date
June 15, 2023 (Anticipated)
Study Completion Date
June 15, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rhode Island Hospital
Collaborators
US Department of Veterans Affairs, Brown University, Intel Corporation, Nuvectra, Boston Scientific Corporation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This research study is being done to test a new device developed for spinal cord injury (SCI) patients. The purpose of this study is to collect data on how the nervous system signals travel within the spinal cord of SCI patients. Once the investigators understand that, they hope to develop a device that may help rehabilitation of SCI patients so that they can regain function in their lower limbs. This study involves some imaging studies (e.g. X-rays etc.), surgical implantation of a portion of the electrical stimulation device, various assessments of body function (e.g. balance, movement, gait), and physical rehabilitation procedures. What is new and experimental is the stimulation/sensing device (Intelligent Spine Interface - Commercial, ISI-C) that will be implanted.
Detailed Description
Intel Corporation, Nuvectra 18. US FDA Regulated: Yes 19. US FDA Regulated Drug: No 20. US FDA Regulated Device: Yes 21. US FDA Investigational New Device (IND)/Investigational Device Exemption (IDE): Yes 22. Human Subjects Protection Review: Pending Review 23. Data Monitoring Committee: Yes 24. FDA Regulated Intervention: Yes 25. Brief Summary: This research study is being done to test a new device developed for spinal cord injury (SCI) patients. The purpose of this study is to collect data on how the nervous system signals travel within the spinal cord of SCI patients. Once the investigators understand that, they hope to develop a device that may help rehabilitation of SCI patients so that they can regain function in their lower limbs. This study involves some imaging studies (e.g. X-rays etc.), surgical implantation of a portion of the electrical stimulation device, various assessments of body function (e.g. balance, movement, gait), and physical rehabilitation procedures. What is new and experimental is the stimulation/sensing device (Intelligent Spine Interface) that will be implanted. 26. Detailed Description: The investigators propose to build an Intelligent Spine Interface (ISI) that will interpret neural information from above a spinal cord injury and transfer that information, via a state-of-the-art artificial neural network-based computer interpreter, to sites below the site of injury and restore control of the lower limbs. At present, activity-based therapies (physical rehabilitation) are only medical practices that can be used to enhance recovery after spinal cord injury. However, most affected patients, who fail to produce active movements voluntarily, experience minimal benefits from such therapies. This study is being done to develop a new treatment modality for Spinal Cord Injury (SCI) patients. The purpose of this study is to collect data on how the nervous system signals travel within the spinal cord of SCI patients. The device being used in this study is termed Intelligent Spine Interface. This device consists of: (1) surgically implanted electrode arrays placed above and below site of spinal cord injury. These arrays are connected to other device components outside the body (like "Ripple System") using specialized wires. (2) "Ripple System" collects readings from implanted electrode arrays. Together, these components are used to stimulate the spinal cord and sense any resulting nervous system signals. (3) Personal computer uses specialized software to interpret the nervous system activity. The use of the ISI-C device in this study is considered investigational. This means the device has not yet been approved by the FDA. The entire study should take about 7-8 months to complete. Study Phases and Procedures: Screening Phase: Subject identification, consent process, eligibility review, preliminary assessments (imaging studies such as x-rays, blood work, physical/neurological exam, medical history, medication review, pregnancy test, electrocardiogram to assess heart health) Pre-rehabilitation Phase: baseline review of SCI related standardized outcome measures to understand if the device/treatment is producing the desired effect on the participant physical function (e.g. gait, balance, ability to walk, muscle tone/spasm, bowel function). Surgery: Pre-surgery testing, anesthesia administration, lead placement above and below the site of injury, wound closure and observation Inpatient Rehabilitation Phase: daily physical rehabilitation sessions in specialized gaits lab, neurostimulation protocol (small electrical pulses will be delivered to the implanted electrode array and any spinal cord activity will be recorded), follow-up SCI-related outcome measures review Surgery: same as above - surgically implanted leads will be removed Follow up phase: Follow-up physical and neurological exams to assess if there is a change in function since baseline

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Cord Injury

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
3 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
SCI Patient
Arm Type
Experimental
Arm Description
Complete or Incomplete Spinal Cord Injury (SCI) patients with Asia Impairment Score (AIS) of A or B between the levels of C7/T1 and T10
Intervention Type
Device
Intervention Name(s)
Intelligent Spine Interface
Other Intervention Name(s)
spinal neuromodulation therapy, spinal cord stimulation device, epidural electrical stimulation system
Intervention Description
ISI-C is a bi-directional, two anatomical location Epidural Electrical Stimulation (EES) system to bridge the lesion core in patients with chronic complete and incomplete spinal cord injury (SCI). This "Intelligent Spine Interface", or ISI will interpret recorded neural information from above a spinal cord lesion and transfer that information, via deep neural network-based interpreters (i.e. models), to stimulation sites (electrodes) below the lesion with the aim of restoring volitional control of the lower limb.
Primary Outcome Measure Information:
Title
Evaluate safety issues
Description
Evaluate safety issues associated with the implantation and use of ISI technology i.e. frequency of device related adverse events
Time Frame
8 months
Secondary Outcome Measure Information:
Title
Neurological Outcome Measures
Description
Assess neurological outcomes before, during, and after ISI implantation in SCI patients via ISNCSCI evaluation
Time Frame
8 months
Title
Functional Outcome Measures
Description
Assess functional outcomes before, during, and after ISI implantation in SCI patients via 6 Minute Walk Test
Time Frame
8 months
Title
Functional Outcome Measures
Description
Assess functional outcomes before, during, and after ISI implantation in SCI patients via 10 minute timed walk test
Time Frame
8 months
Title
Functional Outcome Measures
Description
Assess functional outcomes before, during, and after ISI implantation in SCI patients via Time Up and Go test
Time Frame
8 months
Title
Functional Outcome Measures
Description
Assess functional outcomes before, during, and after ISI implantation in SCI patients via Spinal cord Injury Functional Ambulation Inventory
Time Frame
8 months
Title
Functional Outcome Measures
Description
Assess functional outcomes before, during, and after ISI implantation in SCI patients via Spinal Cord Injury Quality of Life (SCI-QOL): Ambulation Short Form
Time Frame
8 months
Title
Functional Outcome Measures
Description
Assess functional outcomes before, during, and after ISI implantation in SCI patients via SCI Functional Ambulatory Inventory (FAI)
Time Frame
8 months
Title
Functional Outcome Measures
Description
Assess functional outcomes before, during, and after ISI implantation in SCI patients via Berg Balance Scale
Time Frame
8 months
Title
Functional Outcome Measures
Description
Assess functional outcomes before, during, and after ISI implantation in SCI patients via Mini-Best test
Time Frame
8 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: • Adults (men or women) between the ages of 18 and 65 years old Complete or Incomplete SCI with AIS grade of A or B between the levels of C7/T1 and T10 (level and degree of injury based on the international standards for neurological classification of SCI (ISNCSCI)) Focal area of SCI due to trauma SCI date of injury > 1 year prior to enrollment Completed prior SCI rehabilitation program Ability to use both upper extremities to ambulate with a wheelchair or crutches Distance between the conus medullaris and site of injury must be > 4 cm The ability to participate in intensive physical therapy and research > 4 hours per day for 2 weeks Must provide informed consent prior to study participation Exclusion Criteria: • Presence of co-existing lower extremity neuropathy or disorders of the cauda equina Presence of non-traumatic spinal cord pathology Significant cognitive impairment or decreased level of consciousness Presence of an intrathecal baclofen or morphine pump Presence of a cardiac defibrillator or pacemaker Presence of a deep brain stimulator device Patient who has any contraindication to having a MRI performed Severe or disabling joint contractures in the lower extremities Presence of hematologic disorder or medication related coagulopathy that would preclude surgery Lower extremity congenital or acquired deformities Women who are pregnant or who are unwilling to use contraception during the study period Body mass index > 30 Cardiopulmonary comorbidities that preclude participation in intensive physical therapy Known or suspected patient non-compliance during the study period and at follow up Patient life expectancy < 12 months Presence of patient comorbidities or spinal anatomy that would preclude participation in the study per investigators' recommendation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jared S Fridley, MD
Phone
401-793-9197
Email
jared.fridley@lifespan.org
First Name & Middle Initial & Last Name or Official Title & Degree
Owen Leary, BS
Phone
401-606-8388
Email
owen.leary@lifespan.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Borton, PhD
Organizational Affiliation
Brown University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rhode Island Hospital
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02903
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Owen Leary, BS
Phone
401-444-4362
Email
spinalcordstudy@lifespan.org
First Name & Middle Initial & Last Name & Degree
Alexander Chernysh, BS

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Intelligent Spine Interface

We'll reach out to this number within 24 hrs